These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 6583197)

  • 1. Susceptibility of anaerobic bacteria to imipenem.
    Tally FP; Jacobus NV
    J Antimicrob Chemother; 1983 Dec; 12 Suppl D():47-51. PubMed ID: 6583197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of imipenem against anaerobic bacteria.
    Wexler HM; Finegold SM
    Rev Infect Dis; 1985; 7 Suppl 3():S417-25. PubMed ID: 3901206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
    Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
    J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of anaerobic bacteria to Sch 34343 and other antibiotics.
    Glupczynski Y; Gordts B; van der Linden MP; Labbé M; Yourassowsky E; Butzler JP
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():193-8. PubMed ID: 4030548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variations in susceptibility to latamoxef(moxalactam) and cefoxitin within the Bacteroides fragilis group.
    Eley A; Greenwood D
    J Antimicrob Chemother; 1984 Mar; 13(3):245-55. PubMed ID: 6725175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of anaerobic bacteria to Sch 34343 and other beta-lactam antibiotics.
    Jacobus NV; Tally FP; Gorbach SL
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():189-91. PubMed ID: 4030547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan.
    Teng LJ; Hsueh PR; Tsai JC; Liaw SJ; Ho SW; Luh KT
    Antimicrob Agents Chemother; 2002 Sep; 46(9):2908-13. PubMed ID: 12183246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activity of imipenem against gram-positive anaerobic bacteria.
    Dubreuil L; Devos J; Romond C
    Int J Clin Pharmacol Res; 1987; 7(1):39-43. PubMed ID: 3473047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activities of amoxicillin-clavulanic acid and imipenem against anaerobic bacteria isolated from community hospitals.
    Goldstein EJ; Citron DM
    Antimicrob Agents Chemother; 1986 Jan; 29(1):158-60. PubMed ID: 3460519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibacterial activity of meropenem and selected comparative agents against anaerobic bacteria at seven North American centers.
    Sheikh W; Pitkin DH; Nadler H
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S361-6. PubMed ID: 8324148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In-vitro activity of Sch 34343 against anaerobic bacteria.
    Wexler H; Carter WT; Finegold SM
    J Antimicrob Chemother; 1985 Jun; 15 Suppl C():173-6. PubMed ID: 3861606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro activity of N-formimidoyl thienamycin, moxalactam, and other new beta-lactam agents against Bacteroides fragilis: contribution of beta-lactamase to resistance.
    Brown JE; Del Bene VE; Collins CD
    Antimicrob Agents Chemother; 1981 Feb; 19(2):248-52. PubMed ID: 6214986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibacterial effect of imipenem in vitro against important aerobic and anaerobic strains isolated from clinical specimens.
    Klietmann W; Focht J; Nösner K
    Chemioterapia; 1987 Aug; 6(4):243-50. PubMed ID: 3477332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial Susceptibility Patterns of Anaerobic Bacterial Clinical Isolates From 2014 to 2016, Including Recently Named or Renamed Species.
    Byun JH; Kim M; Lee Y; Lee K; Chong Y
    Ann Lab Med; 2019 Mar; 39(2):190-199. PubMed ID: 30430782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of L-627 against anaerobic bacteria.
    Nord CE; Lindmark A; Persson I
    Eur J Clin Microbiol Infect Dis; 1992 Aug; 11(8):757-60. PubMed ID: 1425740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparative in vitro activity of ampicillin, cefoperazone and their combinations with sulbactam, as well as that of other antibiotics against anaerobic organisms].
    Rezvan SP; Sidorenko SV; Budanov SV
    Antibiot Khimioter; 1995 Apr; 40(4):25-9. PubMed ID: 7654095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-lactamases of type culture strains of the Bacteroides fragilis group and of strains that hydrolyse cefoxitin, latamoxef and imipenem.
    Eley A; Greenwood D
    J Med Microbiol; 1986 Feb; 21(1):49-57. PubMed ID: 3485198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology and susceptibility of resistant Bacteroides fragilis group organisms to new beta-lactam antibiotics.
    Heseltine PN; Appleman MD; Leedom JM
    Rev Infect Dis; 1984; 6 Suppl 1():S254-9. PubMed ID: 6585882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Susceptibility of anaerobic bacteria to meropenem.
    Nord CE; Lindmark A; Persson I
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():113-7. PubMed ID: 2553656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility of anaerobic bacteria to antimicrobial agents.
    Collignon PJ; Munro R; Morris G
    Pathology; 1988 Jan; 20(1):48-52. PubMed ID: 3374973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.